Security key
869367102
Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (STRO)
CUSIP: 869367102
Q1 2020 13F Holders as of 31 Mar 2020
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 11,868,607
- Total 13F value
- $116,270,683
- Share change
- +251,216
- SEC-reported price per share
- $10.20
- Number of holders
- 60
- Value change
- +$7,872,102
- Number of buys
- 29
- Number of sells
- 20
- Shares outstanding
- 16,607,375
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2020
Institutions
60
Top holders
10
STRO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2020
Previous quarter: Q4 2019
SUTRO BIOPHARMA, INC. SEC filings
SUTRO BIOPHARMA, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 869367102
Recent filing periods:
Ownership snapshot
Top reported holders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SV Health Investors, LLC
Disclosed value leader
SV Health Investors, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2019
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
SV Health Investors, LLC leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SV Health Investors, LLC's linked filing trail.
Comparable ownership
Top 5
SV Health Investors, LLC
11%
CITADEL ADVISORS LLC
10%
EVENTIDE ASSET MANAGEMENT, LLC
7.5%
Samsara BioCapital, LLC
6.8%
VV Manager LLC
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SV Health Investors, LLC |
13F
Company
|
11%
|
$20,070,000
1,824,542 shares
|
— | 31 Dec 2019 |
| CITADEL ADVISORS LLC |
13F
Company
|
10%
|
$19,019,000
1,728,976 shares
|
— | 31 Dec 2019 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
Company
|
7.5%
|
$13,694,000
1,244,895 shares
|
— | 31 Dec 2019 |
| Samsara BioCapital, LLC |
13F
Company
|
6.8%
|
$12,381,000
1,125,579 shares
|
— | 31 Dec 2019 |
| VV Manager LLC |
13F
Company
|
6%
|
$10,951,000
995,579 shares
|
— | 31 Dec 2019 |
| BlackRock Finance, Inc. |
13F
Company
|
3.9%
|
$7,118,000
647,107 shares
|
— | 31 Dec 2019 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
60
Shares
11,868,607
Rows available
60
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2020 vs Q4 2019 Across Filers
Q4 2019 holders
64
Q1 2020 holders
60
Holder diff
-4
| Investor | Q4 2019 Shares | Q1 2020 Shares | Share Diff | Share Chg % | Q4 2019 value | Q1 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend